ESTRAMUSTINE

SynDRA canonical compound SYN0011719 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	ESR1 \| ESR2 \| MAP1A \| MAP2
Mechanism of action	DNA alkylating agent
Indication	breast cancer \| prostate cancer
Disease area	oncology \| Oncology

All known targets

estracty
Estramustina
LEO-275
LEO275
NSC-89201
RO-22-2296/000
RO-22-2296000
RO-222296000
Ro-22-2296-000
Estramustinum
Emcyt (TN)
Estramustine (USAN/INN)
Estradiol 3-[bis(2-chloroethyl)carbamate]
Ro-22-2296/000
Estra-1,3,5(10)-triene-3,17-diol (17.beta.)-, 3-[bis(2-chloroethyl)carbamate]
[(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] N,N-bis(2-chloroethyl)carbamate
(17beta)-17-hydroxyestra-1(10),2,4-trien-3-yl bis(2-chloroethyl)carbamate
17.beta.-Estradiol 3-[bis(2-chloroethyl)carbamate]
Estramustinum [INN-Latin]
Estramustina [INN-Spanish]
Estradiol 3-(N,N-bis(2-chloroethyl)carbamate)
NSC 89201
17beta-Estradiol 3-(bis(2-chloroethyl)carbamate)
CHEMBL1575
CHEBI:4868
35LT29625A
LEO 275
NCGC00164581-01
Estradiol 3-(bis(2-chloroethyl)carbamate)
Ro-222296000
Estradiol, 3-[bis(2-chloroethyl)carbamate]
Ro-22-2296000
(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl bis(2-chloroethyl)carbamate
RO 21-8837
estra-1,3,5(10)-triene-3,17beta-diol, 3-[bis(2-chloroethyl)carbamate]
disodium (1S,10R,11S,14S,15S)-5-{[bis(2-chloroethyl)carbamoyl]oxy}-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2(7),3,5-trien-14-yl phosphate
CAS-2998-57-4
Estradiol, 3-(bis(2-chloroethyl)carbamate)